interview with peter cook, page-11

Mal, I don't think you can see the battle between Non-GSK's Lani and GSK's Relenza, GSK will stop selling Relenza immediately when LANI is available. If GSK is rational.

I just find something interesting, even if BTA and Daiichi Sankyo do not license the product to a western
drug company, the rest of the world will still ask BTA and DS to supply LANI, the only question is how many they can supply. BTA and DS CAN NOT lose. As BTA shareholders, all we need to do is make sure BTA management do the right thing.